ClinicalTrials.gg
RecruitingNCT06818019WIDUSAUpdated Oct 8, 2026

Withdrawal of Dupilumab in Severe Asthma

A Phase 4 interventional study of Stopping dupilumab in Severe Asthma, sponsored by University Hospital, Toulouse. Recruiting at 29 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-08.

Sponsored by University Hospital, Toulouse · Phase 4, Interventional, and Treatment

How we know · 2 judgments

From the registry’s dates

  • Started Dec 2025; still recruiting 11 months later.
Updated Oct 8, 2026Now RecruitingSite recruiting status changed+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
205
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 296 studies in Asthma with a site in France — 44 open to participants now, 57 under way, 8 of them phase 3. Asthma · France.

Planned enrollment
104th of 204
205 · median 209
Started
2025
with 11 others
Phase 4
20 of 296
2 open now
Primary completion
2027-12
later than 34 of 56 live
Registered
275th of 296
by date
Lead sponsor
8 of 296
University Hospital, Toulouse

Among the 296 studies in Asthma with a site in France, this one is the 104th largest by planned enrollment of the 204 interventional ones that give a count, is one of 12 that started in 2025, is one of 20 in phase 4, reaches primary completion later than 34 of the 56 other live ones, and was the 275th registered.

Asthma

4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.

Browse Asthma studies →

Open to participants now

44 of the 296 studies in Asthma with a site in France are open now. Recruiting first, the newest first:

38 more — sign in →

All 44 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 416 Asthma studies recruiting now, 141 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 146 take children under 18; 105 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 296 studies in Asthma with a site in France, or all of them as a file.
02

Study summary

Asthma management has been revolutionised by the development of biological therapies. Dupilumab is an anti-interleukin4 receptor marketed in 2020 for severe asthmatic patients with 2 exacerbations or more within the last 12 months. Although data showed that safety and efficacy of dupilumab are sustained when treatment is extended up to 3 years, no study has emerged regarding dupilumab discontinuation. This study aims to demonstrate the non-inferiority regarding strategy failure at 24 months of stopping dupilumab (intervention group) compared with its continuation (control group) in controlled asthma patients receiving this drug for at least 3 years.

Read the detailed description

Although dupilumab is a very effective drug in severe asthma, the optimal duration of this drug is unknown. However, this is a crucial question given the high cost of dupilumab and the lack of data regarding the long-term inhibition of type 2 pathway. Studies on biologic discontinuation are scarce in severe asthma. Studies with other biologics have shown that discontinuation of these drugs is feasible particularly for patients with low exacerbation rate before stopping treatment. In a study with pooled asthma biologics, 1247 (25.1%) stopped the biologic among the 4958 biologic users (including 19.8% of dupilumab users). Among all stoppers, 10.2% failed discontinuation of the asthma biologic in the 6 months after stopping, defined as an increase of 50% or more in exacerbations. Among patients who continued the biologic, 9.5% had an increase of 50% or more in exacerbations during a 6-month period, showing a similar failing rate. Such data for dupilumab discontinuation are lacking.

In this study, we plan to include patients with controlled asthma treated with dupilumab for at least 3 years who will be randomised to stopping dupilumab or dupilumab continuation with a follow-up of 24 months.

In total, 5 visits will occur for each patient: the inclusion/randomisation visit (baseline), 3 follow-up visits at month 6, month 12, month 24 as usually done in severe asthma, and a phone call visit at 18 months for exacerbations, treatments and adverse events collection. At each onsite visit, asthma medications, concomitant treatments, nasal polyp score (if applicable), number of exacerbations, Asthma Control Questionnaire, Severe Asthma Questionnaire, Treatment Burden Questionnaire and Sino-Nasal Outcome Test-22 scores, Forced expiratory volume in one second, Forced vital capacity, Fraction exhaled nitric oxide (if available), blood eosinophil, neutrophil and lymphocyte counts, adverse events, hospital admissions, and unscheduled medical visits will be recorded.

03

Conditions studied

  • Severe Asthma

Browse trials for

Keywords

  • severe asthma
  • dupilumab
  • exacerbation
  • discontinuation
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients ≥ 18 years old
  • Treated with dupilumab for at least 36 months for severe asthma
  • Well controlled asthma defined by an Asthma Control Questionnaire score ≥ 18 and 0 or 1 exacerbation within the year prior to the inclusion visit

Exclusion criteria

Exclusion Criteria:

  • Patients who refuse to discontinue dupilumab, for any reason
  • Patients with ≤ 30% of predicted values
  • Patients treated by an oral dose ≥ 10 mg/day (in prednisone equivalent)
  • Patients who have to discontinue dupilumab for a reason other than controlled asthma, such as an adverse drug reaction, a planned or current pregnancy, or a planned switch to another biologic indicated in severe asthma
  • Patients who have to continue dupilumab for the treatment of comorbidities apart from nasal polyposis
  • Active smoking
  • Pregnancy or breastfeeding
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
205 participants (estimated)

Study arms

  • Experimental
    Stopping dupilumab

    The experimental strategy comprises stopping dupilumab with no dose-reducing or interval of time-increasing strategy from the day of inclusion/randomisation

    Drug: Stopping dupilumab

  • No intervention
    Dupilumab continuation

    Dupilumab continuation at the same dose and same interval as baseline

Interventions

  • DrugStopping dupilumab

    Stopping dupilumab with no dose-reducing or interval of time-increasing strategy

This study also gives DupilumabStudies of DupilumabDupilumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. Strategy failure

    Proportion of patients with strategy failure defined as patients with an annualised number of asthma exacerbations ≥ 2 and/or dupilumab resume or switch to another biologic within 24 months following randomisation

    Time frame: 24 months

Secondary outcomes

  1. Change in asthma control test score

    Comparing the interventional group with the control group regarding the change in asthma control test score at 6, 12 and 24 months compared to baseline. The asthma control test score is a self-administered questionnaire consisting of 5 questions related to the frequency of asthma symptoms and the use of rescue treatments over the past 4 weeks. The score ranges from 5 (poorest control) to 25 (perfect control)

    Time frame: 6, 12 and 24 months

  2. Resumption of dupilumab

    Proportion of patients with resumption of dupilumab in the interventional group (stopping dupilumab) at 6, 12 and 24 months

    Time frame: 6, 12 and 24 months

  3. Adverse events or serious adverse events

    Proportion of patients with adverse events or serious adverse events in both groups

    Time frame: 24 months

  4. Time to loss of control

    Comparing the interventional group with the control group regarding the time between baseline to loss of control defined by a reduction of 5 points or more on asthma test control score

    Time frame: 24 months

  5. First exacerbation

    Comparing the interventional group with the control group regarding the time to first exacerbation

    Time frame: 24 months

  6. Number of exacerbations

    Comparing the interventional group with the control group regarding the number of exacerbations within 24 months

    Time frame: 24 months

  7. Proportion of patients with ≥ 1 exacerbation(s)

    Comparing the interventional group with the control group regarding the proportion of patients with ≥ 1 exacerbation(s) or severe exacerbation(s) at 6, 12 and 24 months. A severe exacerbation is defined as an emergency room visit or hospital admission or death related to asthma exacerbation.

    Time frame: 6, 12 and 24 months

  8. Change in quality of life

    Comparing the interventional group with the control group regarding the change in quality of life at 6, 12 and 24 months compared to baseline. The change in the severe asthma questionnary quality of life score and the Burden of Treatment Questionnaire score at 6, 12 and 24 months compared to baseline. The severe asthma questionnary is a health-related quality of life questionnaire validated for use in severe asthma. It is scored using the mean value of 16 items (severe asthma questionnary score) in addition to a single item global rating of health-related quality of life. The Burden of Treatment Questionnaire is a 15-item questionnaire that assesses the treatment burden of chronic diseases.

    Time frame: 6, 12 and 24 months

  9. Change in lung function

    The lung function change is a qualitative clinical criteria of failure/success of the strategy. This failure is made up of 3 components : Forced Expiratory Volume in 1 second (in L and % predicted, pre- and post-bronchodilator), Forced Vital Capacity (in L and % predicted) and forced exhaled nitric oxide (in ppb) at 6, 12 and 24 months compared to baseline

    Time frame: 6, 12 and 24 months

  10. Change in the daily dose of oral corticosteroids

    Comparing the interventional group with the control group regarding the change in the daily dose (mg/day) of oral corticosteroids (in prednisone equivalent) at 6, 12 and 24 months compared to baseline

    Time frame: 6, 12 and 24 months

  11. Change in the daily dose of inhaled corticosteroids

    Comparing the interventional group with the control group regarding the change in the daily dose (μg/day) of inhaled corticosteroids (in beclomethasone equivalent) at 6, 12 and 24 months

    Time frame: 6, 12 and 24 months

  12. Effect on nasal polyposis

    Comparing the interventional group with the control group regarding the change in nasal polyposis endoscopic score (if available) and Sino-Nasal Outcome Test-22 score at 6, 12 and 24 months compared to baseline. The french version of Sino-Nasal Outcome Test-22 is a further modification of the Sino-Nasal Outcome Test-20, a fully validated and easy-to-use outcome measure in rhinology. In addition to the normal 20-item version of the Sino-Nasal Outcome Test, 2 additional items were measured, nasal blockage, and loss of sense of taste and smell. The 22-question Sino-Nasal Outcome Test-22 is scored as 0 (no problem) to 5 (problem as bad as it can be) with a total range from 0 to 110 (higher scores indicate poorer outcomes).

    Time frame: 6, 12 and 24 months

07

Study locations

12 of 29 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for Dec 2027, 24 months after the start.

Of 90 non-industry phase 4 interventional studies under Asthma, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 51. This study's planned 24 months is below that.

Counting every sponsor, half of 156 studies reached it within 24 months; a quarter within 11 and three quarters within 37.

Start moved once since we started tracking on Sep 25, 2026: Apr 2025 → Dec 2025, on Oct 8, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 19, 2024
First posted
Feb 10, 2025
StartActual
Dec 15, 2025was Apr 2025
Primary completionEst.
Dec 31, 2027
CompletionEst.
Dec 31, 2029
Last update
Oct 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 8, 2026
Sites
28 sites added, 28 sites removed. CHU de Toulouse is now Recruiting
Show 28 added (28 France)
  • CHU Amiens-Picardie · Amiens, France
  • CHR d'Angers · Angers, France
  • CH de Bayonne · Bayonne, France
  • CHU de Besançon · Besançon, France
  • CHU de Brest · Brest, France
  • CHU de Caen · Caen, France
  • CH de Cannes · Cannes, France
  • CHU de Clermont-Ferrand · Clermont-Ferrand, France
  • CHI de Créteil · Créteil, France
  • CHU de Dijon · Dijon, France
  • CH Annecy Genevois · Epagny-Metz-Annecy, France
  • CHU Grenoble-Alpes · La Tronche, France
  • Hôpital Kremlin Bicêtre · Le Kremlin-Bicêtre, France
  • CH Le Mans · Le Mans, France
  • Institut Coeur Poumon, CHU de Lille · Lille, France
  • Hôpital Croix Rousse · Lyon, France
  • Hôpital Avicenne · Paris, France
  • Hôpital Européen Georges Pompidou · Paris, France
  • Hôpital Bichât · Paris, France
  • CHU de Bordeaux · Pessac, France
  • Hôpital Lyon Sud · Pierre-Bénite, France
  • CHU de Reims · Reims, France
  • CH de Roubaix · Roubaix, France
  • CHU de La Réunion · Saint-Denis, France
  • CHU de Nantes · Saint-Herblain, France
  • Nouvel Hôpital Civil · Strasbourg, France
  • Hôpital Foch · Suresnes, France
  • Hôpital Tarbes Lourdes · Tarbes, France
Show 28 removed
  • CHU Amiens-Picardie · Amiens, France
  • CHR d'Angers · Angers, France
  • CH de Bayonne · Bayonne, France
  • CHU de Besançon · Besançon, France
  • CHU de Brest · Brest, France
  • CHU de Caen · Caen, France
  • CH de Cannes · Cannes, France
  • CHU de Clermont-Ferrand · Clermont-Ferrand, France
  • CHI de Créteil · Créteil, France
  • CHU de Dijon · Dijon, France
  • CH Annecy Genevois · Epagny-Metz-Annecy, France
  • CHU Grenoble-Alpes · La Tronche, France
  • Hôpital Kremlin Bicêtre · Le Kremlin-Bicêtre, France
  • CH Le Mans · Le Mans, France
  • Institut Coeur Poumon, CHU de Lille · Lille, France
  • Hôpital Croix Rousse · Lyon, France
  • Hôpital Avicenne · Paris, France
  • Hôpital Européen Georges Pompidou · Paris, France
  • Hôpital Bichât · Paris, France
  • CHU de Bordeaux · Pessac, France
  • Hôpital Lyon Sud · Pierre-Bénite, France
  • CHU de Guadeloupe · Pointe-à-Pitre, France
  • CHU de Reims · Reims, France
  • CH de Roubaix · Roubaix, France
  • CHU de Nantes · Saint-Herblain, France
  • Nouvel Hôpital Civil · Strasbourg, France
  • Hôpital Foch · Suresnes, France
  • Hôpital Tarbes Lourdes · Tarbes, France
Oct 8, 2026
Start date
Apr 2, 2025→Dec 15, 2025 (actual)
Oct 8, 2026
Show all 1 update
  1. Oct 8, 2026
    Not yet recruiting→Recruiting
    28 sites added, 28 sites removed. CHU de Toulouse is now Recruiting
    Show 28 added (28 France)
    • CHU Amiens-Picardie · Amiens, France
    • CHR d'Angers · Angers, France
    • CH de Bayonne · Bayonne, France
    • CHU de Besançon · Besançon, France
    • CHU de Brest · Brest, France
    • CHU de Caen · Caen, France
    • CH de Cannes · Cannes, France
    • CHU de Clermont-Ferrand · Clermont-Ferrand, France
    • CHI de Créteil · Créteil, France
    • CHU de Dijon · Dijon, France
    • CH Annecy Genevois · Epagny-Metz-Annecy, France
    • CHU Grenoble-Alpes · La Tronche, France
    • Hôpital Kremlin Bicêtre · Le Kremlin-Bicêtre, France
    • CH Le Mans · Le Mans, France
    • Institut Coeur Poumon, CHU de Lille · Lille, France
    • Hôpital Croix Rousse · Lyon, France
    • Hôpital Avicenne · Paris, France
    • Hôpital Européen Georges Pompidou · Paris, France
    • Hôpital Bichât · Paris, France
    • CHU de Bordeaux · Pessac, France
    • Hôpital Lyon Sud · Pierre-Bénite, France
    • CHU de Reims · Reims, France
    • CH de Roubaix · Roubaix, France
    • CHU de La Réunion · Saint-Denis, France
    • CHU de Nantes · Saint-Herblain, France
    • Nouvel Hôpital Civil · Strasbourg, France
    • Hôpital Foch · Suresnes, France
    • Hôpital Tarbes Lourdes · Tarbes, France
    Show 28 removed
    • CHU Amiens-Picardie · Amiens, France
    • CHR d'Angers · Angers, France
    • CH de Bayonne · Bayonne, France
    • CHU de Besançon · Besançon, France
    • CHU de Brest · Brest, France
    • CHU de Caen · Caen, France
    • CH de Cannes · Cannes, France
    • CHU de Clermont-Ferrand · Clermont-Ferrand, France
    • CHI de Créteil · Créteil, France
    • CHU de Dijon · Dijon, France
    • CH Annecy Genevois · Epagny-Metz-Annecy, France
    • CHU Grenoble-Alpes · La Tronche, France
    • Hôpital Kremlin Bicêtre · Le Kremlin-Bicêtre, France
    • CH Le Mans · Le Mans, France
    • Institut Coeur Poumon, CHU de Lille · Lille, France
    • Hôpital Croix Rousse · Lyon, France
    • Hôpital Avicenne · Paris, France
    • Hôpital Européen Georges Pompidou · Paris, France
    • Hôpital Bichât · Paris, France
    • CHU de Bordeaux · Pessac, France
    • Hôpital Lyon Sud · Pierre-Bénite, France
    • CHU de Guadeloupe · Pointe-à-Pitre, France
    • CHU de Reims · Reims, France
    • CH de Roubaix · Roubaix, France
    • CHU de Nantes · Saint-Herblain, France
    • Nouvel Hôpital Civil · Strasbourg, France
    • Hôpital Foch · Suresnes, France
    • Hôpital Tarbes Lourdes · Tarbes, France
    Start date Apr 2, 2025→Dec 15, 2025 (now actual)
    + 3 other changes: index terms, verification date and oversight details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06818019
Responsible party
Sponsor
First posted
Feb 10, 2025
Start date
Dec 15, 2025
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2029 (estimated)
Last update
Oct 8, 2026

Study contacts

Laurent GUILLEMINAULT, Md, PhD
Contact
guilleminault.l@chu-toulouse.fr
0567771850 ext. +33
Laurent GUILLEMINAULT, MD, PhD
principal investigator · University Hospital, Toulouse

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dupilumab

Start the discussion